{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:10:11Z","timestamp":1790086211668,"version":"4.0.1"},"reference-count":47,"publisher":"Association for Research in Vision and Ophthalmology (ARVO)","issue":"8","license":[{"start":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T00:00:00Z","timestamp":1593648000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trans. Vis. Sci. Tech."],"published-print":{"date-parts":[[2020,7,2]]},"DOI":"10.1167\/tvst.9.8.5","type":"journal-article","created":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T14:31:58Z","timestamp":1593700318000},"page":"5","source":"Crossref","is-referenced-by-count":10,"title":["Microporous Drug Delivery System for Sustained Anti-VEGF Delivery to the Eye"],"prefix":"10.1167","volume":"9","author":[{"given":"Chengxin","family":"Zhou","sequence":"first","affiliation":[{"name":"Boston Keratoprosthesis Laboratory, Department of Ophthalmology, Massachusetts Eye and Ear and Schepens Eye Research Institute, Boston, MA, USA"},{"name":"Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arushi","family":"Singh","sequence":"additional","affiliation":[{"name":"Boston Keratoprosthesis Laboratory, Department of Ophthalmology, Massachusetts Eye and Ear and Schepens Eye Research Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Qian","sequence":"additional","affiliation":[{"name":"Boston Keratoprosthesis Laboratory, Department of Ophthalmology, Massachusetts Eye and Ear and Schepens Eye Research Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Wolkow","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, MA, USA"},{"name":"David G. Cogan Laboratory of Eye Pathology and Ophthalmic Plastic Surgery Service, Massachusetts Eye and Ear Infirmary, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claes H.","family":"Dohlman","sequence":"additional","affiliation":[{"name":"Boston Keratoprosthesis Laboratory, Department of Ophthalmology, Massachusetts Eye and Ear and Schepens Eye Research Institute, Boston, MA, USA"},{"name":"Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demetrios G.","family":"Vavvas","sequence":"additional","affiliation":[{"name":"Angiogenesis Laboratory, Retina Service, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Chodosh","sequence":"additional","affiliation":[{"name":"Boston Keratoprosthesis Laboratory, Department of Ophthalmology, Massachusetts Eye and Ear and Schepens Eye Research Institute, Boston, MA, USA"},{"name":"Harvard Medical School, Boston, MA, USA"},{"name":"Disruptive Technology Laboratory (D.T.L.), Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleftherios I.","family":"Paschalis","sequence":"additional","affiliation":[{"name":"Boston Keratoprosthesis Laboratory, Department of Ophthalmology, Massachusetts Eye and Ear and Schepens Eye Research Institute, Boston, MA, USA"},{"name":"Harvard Medical School, Boston, MA, USA"},{"name":"Disruptive Technology Laboratory (D.T.L.), Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27","reference":[{"key":"bib1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/archopht.126.1.71","article-title":"Promotion of graft survival by vascular endothelial growth factor a neutralization after high-risk corneal transplantation","volume":"126","author":"Bachmann","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"bib2","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.survophthal.2012.01.007","article-title":"Corneal neovascularization: an anti-VEGF therapy review","volume":"57","author":"Chang","year":"2012","journal-title":"Surv Ophthalmol"},{"key":"bib3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jtos.2012.01.005","article-title":"Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin)","volume":"10","author":"Stevenson","year":"2012","journal-title":"Ocul Surf"},{"key":"bib4","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3109\/09273948.2010.486100","article-title":"Immune privilege of corneal allografts","volume":"18","author":"Niederkorn","year":"2010","journal-title":"Ocul Immunol Inflamm"},{"key":"bib5","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1097\/TP.0000000000000512","article-title":"VEGF-trap aflibercept significantly improves long-term graft survival in high-risk corneal transplantation","volume":"99","author":"Dohlman","year":"2015","journal-title":"Transplantation"},{"key":"bib6","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0039-6257(98)00035-6","article-title":"Ocular neovascularization: an epidemiologic review","volume":"43","author":"Lee","year":"1998","journal-title":"Surv Ophthalmol"},{"key":"bib7","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/00055735-200108000-00002","article-title":"Corneal neovascularization","volume":"12","author":"Chang","year":"2001","journal-title":"Curr Opin Ophthalmol"},{"key":"bib8","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2174\/187221309789257450","article-title":"Corneal neovascularization: molecular events and therapeutic options","volume":"3","author":"Shakiba","year":"2009","journal-title":"Recent Pat Inflamm Allergy Drug Discov"},{"key":"bib9","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00417-007-0684-4","article-title":"Bevacizumab (Avastin) eye drops inhibit corneal neovascularization","volume":"246","author":"Bock","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"bib10","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1016\/j.ophtha.2008.02.013","article-title":"The effect of topical bevacizumab on corneal neovascularization","volume":"115","author":"Kim","year":"2008","journal-title":"Ophthalmology"},{"key":"bib11","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1001\/archophthalmol.2009.18","article-title":"Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study","volume":"127","author":"Dastjerdi","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"bib12","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s00417-009-1099-1","article-title":"Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization","volume":"247","author":"Koenig","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"bib13","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1007\/s00347-007-1512-2","article-title":"Inhibition of angiogenesis in the anterior chamber of the eye","volume":"104","author":"Bock","year":"2007","journal-title":"Ophthalmologe"},{"key":"bib14","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1136\/bjo.2006.107912","article-title":"Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin)","volume":"91","author":"Manzano","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"bib15","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1111\/aos.2010.88.issue-8","article-title":"The inhibitory effect of different concentrations of topical bevacizumab on corneal neovascularization","volume":"88","author":"Habot-Wilner","year":"2010","journal-title":"Acta Ophthalmologica"},{"key":"bib16","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jconrel.2010.08.028","article-title":"Barrier analysis of periocular drug delivery to the posterior segment","volume":"148","author":"Ranta","year":"2010","journal-title":"J Control Release"},{"key":"bib17","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.preteyeres.2016.12.001","article-title":"Pharmacokinetic aspects of retinal drug delivery","volume":"57","author":"Del Amo","year":"2017","journal-title":"Prog Retin Eye Res"},{"key":"bib18","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/aos.2009.87.issue-6","article-title":"Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization","volume":"87","author":"You","year":"2009","journal-title":"Acta Ophthalmol"},{"key":"bib19","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1136\/bjophthalmol-2012-302435","article-title":"Intravitreal injections at the Massachusetts Eye and Ear Infirmary: analysis of treatment indications and postinjection endophthalmitis rates","volume":"97","author":"Englander","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"bib20","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1167\/tvst.5.2.11","article-title":"A Drug Delivery System for Administration of Anti-TNF-alpha Antibody","volume":"5","author":"Robert","year":"2016","journal-title":"Transl Vis Sci Technol"},{"key":"bib21","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1167\/iovs.16-20339","article-title":"Sustained subconjunctival delivery of infliximab protects the cornea and retina following alkali burn to the eye","volume":"58","author":"Zhou","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib22","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.ajpath.2017.02.005","article-title":"Mechanisms of retinal damage after ocular alkali burns","volume":"187","author":"Paschalis","year":"2017","journal-title":"Am J Pathol"},{"key":"bib23","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1167\/tvst.3.5.4","article-title":"Removal of silicone oil from intraocular lens using novel surgical materials","volume":"3","author":"Paschalis","year":"2014","journal-title":"Transl Vis Sci Technol"},{"key":"bib24","article-title":"Avastin full prescribing information","author":"Genentech","year":"2019"},{"key":"bib25","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1097\/ICO.0000000000000071","article-title":"Alkali burn to the eye: protection using TNF-a inhibition","volume":"33","author":"Cade","year":"2014","journal-title":"Cornea"},{"key":"bib26","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1097\/ICL.0000000000000071","article-title":"Tumor necrosis factor-a inhibitors as a treatment of corneal hemangiogenesis and lymphangiogenesis","volume":"41","author":"Ferrari","year":"2015","journal-title":"Eye Contact Lens"},{"key":"bib27","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1021\/cm703005g","article-title":"Physical and optical properties of inverse opal CeO2 photonic crystals","volume":"20","author":"Waterhouse","year":"2008","journal-title":"Chem Mater"},{"key":"bib28","first-page":"4593","article-title":"Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders","volume":"57","author":"Presta","year":"1997","journal-title":"Cancer Res"},{"key":"bib29","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","article-title":"Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab","volume":"37","author":"Avery","year":"2017","journal-title":"Retina"},{"key":"bib30","first-page":"2148","article-title":"Standard models of corneal injury using alkali-immersed filter discs","volume":"30","author":"Ormerod","year":"1989","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bib31","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.ejpb.2014.12.029","article-title":"Silk hydrogels for sustained ocular delivery of anti-vascular endothelial growth factor (anti-VEGF) therapeutics","volume":"95","author":"Lovett","year":"2015","journal-title":"Eur J Pharm Biopharm"},{"key":"bib32","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/s12272-010-0714-3","article-title":"Effect of sodium carboxymethylcellulose and fucidic acid on the gel characterization of polyvinylalcohol-based wound dressing","volume":"33","author":"Lim","year":"2010","journal-title":"Arch Pharm Res"},{"key":"bib33","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/02713680802607740","article-title":"The anti-inflammatory effect of subconjunctival bevacizumab on chemically burned rat corneas","volume":"34","author":"Oh","year":"2009","journal-title":"Curr Eye Res"},{"key":"bib34","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00417-009-1101-y","article-title":"Anti-VEGF monoclonal antibody-induced regression of corneal neovascularization and inflammation in a rabbit model of herpetic stromal keratitis","volume":"247","author":"Saravia","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"bib35","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.3109\/02713683.2011.601840","article-title":"The impact of subconjuctivally injected EGF and VEGF inhibitors on experimental corneal neovascularization in rat model","volume":"36","author":"Sener","year":"2011","journal-title":"Curr Eye Res"},{"key":"bib36","doi-asserted-by":"publisher","first-page":"195","DOI":"10.5483\/BMBRep.2013.46.4.193","article-title":"Accelerating repaired basement membrane after bevacizumab treatment on alkali-burned mouse cornea","volume":"46","author":"Lee KJ","year":"2013","journal-title":"BMB Rep"},{"key":"bib37","doi-asserted-by":"publisher","first-page":"e94205","DOI":"10.1371\/journal.pone.0094205","article-title":"Mechanisms controlling the effects of bevacizumab (Avastin) on the inhibition of early but not late formed corneal neovascularization","volume":"9","author":"Chen","year":"2014","journal-title":"PLOS ONE"},{"key":"bib38","doi-asserted-by":"publisher","first-page":"299","DOI":"10.5301\/ejo.5000391","article-title":"The effect of subconjunctival ranibizumab on corneal and anterior segment neovascularization: study on an animal model","volume":"24","author":"Liarakos","year":"2014","journal-title":"Eur J Ophthalmol"},{"key":"bib39","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.ajo.2007.11.003","article-title":"Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model","volume":"145","author":"Papathanassiou","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"bib40","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ajo.2016.12.026","article-title":"Elevated neutrophil elastase in tears of ocular graft-versus-host disease patients","volume":"176","author":"Arafat","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"bib41","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ophtha.2013.06.049","article-title":"Neutrophil collagenase, gelatinase, and myeloperoxidase in tears of patients with stevens-johnson syndrome and ocular cicatricial pemphigoid","volume":"121","author":"Arafat","year":"2014","journal-title":"Ophthalmology"},{"key":"bib42","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1097\/ICO.0000000000000893","article-title":"Tear matrix metalloproteinases and myeloperoxidase levels in patients with Boston keratoprosthesis type I","volume":"35","author":"Robert","year":"2016","journal-title":"Cornea"},{"key":"bib43","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/bjo.87.1.101","article-title":"Pericyte recruitment in human corneal angiogenesis: an ultrastructural study with clinicopathological correlation","volume":"87","author":"Cursiefen","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"bib44","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/jbm.1043","article-title":"Hemocompatibility, biocompatibility, inflammatory and in vivo studies of primary reference materials low-density polyethylene and polydimethylsiloxane: a review","volume":"58","author":"Belanger","year":"2001","journal-title":"J Biomed Mater Res"},{"key":"bib45","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s13534-011-0033-8","article-title":"Flexible, stretchable and implantable PDMS encapsulated cable for implantable medical device","volume":"1","author":"Kim","year":"2011","journal-title":"Biomed Eng Lett"},{"key":"bib46","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/(ISSN)1097-4636","article-title":"In vivo induction of macrophage Ia antigen (MHC class II) expression by biomedical polymers in the cage implant system","volume":"28","author":"Petillo","year":"1994","journal-title":"J Biomed Mater Res"},{"key":"bib47","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s13346-018-0520-x","article-title":"Freeze-dried matrices for ocular administration of bevacizumab: a comparison between subconjunctival and intravitreal administration in rabbits","volume":"8","author":"Burgalassi","year":"2018","journal-title":"Drug Deliv Transl Res"}],"container-title":["Translational Vision Science & Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/tvst.arvojournals.org\/article.aspx?articleid=2770242","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T14:32:00Z","timestamp":1593700320000},"score":1,"resource":{"primary":{"URL":"https:\/\/tvst.arvojournals.org\/article.aspx?articleid=2770242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,2]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,7,1]]}},"URL":"https:\/\/doi.org\/10.1167\/tvst.9.8.5","relation":{},"ISSN":["2164-2591"],"issn-type":[{"value":"2164-2591","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7,2]]}}}